In partnership with
In partnership with
- Only CureMatch’s innovative AI-based technology is transforming cancer treatment by providing personalized insights into NGS diagnostics.
- The software analyzes a patient’s tumor profile to recommend the biology driven custom personalized combination therapy options which are scored, filtered & prioritised based on the fitness of molecular matching.
- This personalized approach has the potential to significantly improve outcomes in real time by offering more effective and precise therapy options for cancer patients based on a curated knowledge repository.
- Developed and validated by globally renowned precision oncology experts.
Why CUREMATCH?
The CureMatch platform is a powerful complement to the therapeutic decision-making process because it allows for the combination of approved therapies with off-label treatments that have been approved for other cancer indications. The algorithm draws upon a comprehensive range of data, including genomics, pharmacology, drug mechanisms, clinical trials, resistance characteristics, and toxicity profiles, to identify the best potential treatment combinations.
Who would benefit from CUREMATCH?
Consider CureMatch for the following scenarios:
- Where there are no applicable clinical trials in India or if patients do not meet inclusion criteria
- Patients who are withdrawn from a clinical trial due to toxicity or lack of therapeutic response.
- Have rare cancers with few treatment options
- Aggressive tumors that don’t seem to be responding to standard lines of therapy
- Advanced systemic tumors that are resistant to standard therapy.
- To evaluate a more cost-effective treatment combination
Isn't NGS enough?
Standard molecular testing reports contain drugs targeted for a particular mutation CureMatch is complementary to NGS lab services, which serve as inputs to initiate CureMatch analysis.
Assesses & quantifies
CureMatch assesses drugs in custom combinations systematically and quantifies the fitness of molecular matching of each therapy option.
300 available cancer drugs
Of the over 4.5 million possible combinations of 300 available cancer drugs, CureMatch can present known and unknown treatment options.
Molecular therapy matching
The customized unique combinations account for more than 99% of top scoring molecular therapy matches per patient for any cancer.
Knowledge database
Matching is based on an expert-guided-manually-curated algorithm, which presents options from an extensive knowledge database curated for over 7 years and continuously updated.
Scored & filtered
Only CureMatch provides biology driven combination therapy options which are scored, filtered and prioritised based on relevance.
Assesses & quantifies
CureMatch assesses drugs in custom combinations systematically and quantifies the fitness of molecular matching of each therapy option.
300 available cancer drugs
Of the over 4.5 million possible combinations of 300 available cancer drugs, CureMatch can present known and unknown treatment options.
Molecular therapy matching
The customized unique combinations account for more than 99% of top scoring molecular therapy matches per patient for any cancer.
Knowledge database
Matching is based on an expert-guided-manually-curated algorithm, which presents options from an extensive knowledge database curated for over 7 years and continuously updated.
Scored & filtered
Only CureMatch provides biology driven combination therapy options which are scored, filtered and prioritised based on relevance.
Assesses & quantifies
CureMatch assesses drugs in custom combinations systematically and quantifies the fitness of molecular matching of each therapy option.
300 available cancer drugs
Of the over 4.5 million possible combinations of 300 available cancer drugs, CureMatch can present known and unknown treatment options.
Molecular therapy matching
The customized unique combinations account for more than 99% of top scoring molecular therapy matches per patient for any cancer.
Knowledge database
Matching is based on an expert-guided-manually-curated algorithm, which presents options from an extensive knowledge database curated for over 7 years and continuously updated.
Scored & filtered
Only CureMatch provides biology driven combination therapy options which are scored, filtered and prioritised based on relevance.
Assesses & quantifies
CureMatch assesses drugs in custom combinations systematically and quantifies the fitness of molecular matching of each therapy option.
300 available cancer drugs
Of the over 4.5 million possible combinations of 300 available cancer drugs, CureMatch can present known and unknown treatment options.
Molecular therapy matching
The customized unique combinations account for more than 99% of top scoring molecular therapy matches per patient for any cancer.
Knowledge database
Matching is based on an expert-guided-manually-curated algorithm, which presents options from an extensive knowledge database curated for over 7 years and continuously updated.
Scored & filtered
Only CureMatch provides biology driven combination therapy options which are scored, filtered and prioritised based on relevance.
To learn more refer to the website: https://www.curematch.com/
The VCR Park and CUREMATCH partnership brings improved access to next-generation healthcare solutions for cancer patients.
Multidisciplinary team of molecular biologists, molecular pathologists and
oncologists
Providing access to cutting edge clinical science both in India and US
Combination therapy matching and counselling localized to Indian context
To learn more refer to the website: https://www.vcrpark.com/
Multidisciplinary team of molecular biologists, molecular pathologists and
oncologists
Providing access to cutting edge clinical science both in India and US
Combination therapy matching and counselling localized to Indian context
To learn more refer to the website: https://vcrpark.com/
VCR Park-CUREMATCH Process
TAT: 2-3 working days
TAT: 2-3 working days
TAT: 2-3 working days
Cases will be reviewed in our digital precision tumor board once every 6 weeks on a voluntary basis.
Team
CUREMATCH
VCR PARK
CUREMATCH
VCR PARK
Razelle Kurzrock, MD
Chief medical advisor & Co-founder, CUREMATCH Director, Rare tumor clinic, UCSD
- A board-certified medical oncologist and a renowned expert in precision medicine
- With over 400 peer-reviewed publications, she has a strong record of competitive grant funding
- Developed one of the largest Phase I clinical trial programs at MD Anderson Cancer Center, Texas
- Executive Committee of Board of Directors, National Comprehensive Cancer Network® (NCCN®)
Himabindu Gaddipati, MD, EMTM
Chairman and MD, VCR Park CEO, Lumiseek
- Clinical hemato-oncologist and geneticist
- Over 2 decades of expertise in Basic science, Clinical trials, Precision medicine, Technology
commercialization (Wharton), Regulation (FDA) and IP (NCI) - Founder at Biolara Inc.
- Executive Director, Queens NRI Hospital, Visakhapatnam
Payal Keswarpu, MD, DNB
Pathology Lab Director, VCR Park
- Pathologist with 20 years of experience in molecular pathology services and development of
esoteric assays - Experience in working with laboratories in precision oncology space in US & India
- Expertise in Quality management process and audit
- Established research partnership for oncology products and services with academic and hospital-based programs
Razelle Kurzrock, MD
Chief medical advisor & Co-founder, CUREMATCH Director, Rare tumor clinic, UCSD
- A board-certified medical oncologist and a renowned expert in precision medicine
- With over 400 peer-reviewed publications, she has a strong record of competitive grant funding
- Developed one of the largest Phase I clinical trial programs at MD Anderson Cancer Center, Texas
- Executive Committee of Board of Directors, National Comprehensive Cancer Network® (NCCN®)
Himabindu Gaddipati, MD, EMTM
Chairman and MD, VCR Park CEO, Lumiseek
- Clinical hemato-oncologist and geneticist
- Over 2 decades of expertise in Basic science, Clinical trials, Precision medicine, Technology
commercialization (Wharton), Regulation (FDA) and IP (NCI) - Founder at Biolara Inc.
- Executive Director, Queens NRI Hospital, Visakhapatnam
Payal Keswarpu, MD, DNB
Pathology Lab Director, VCR Park
- Pathologist with 20 years of experience in molecular pathology services and development of
esoteric assays - Experience in working with laboratories in precision oncology space in US & India
- Expertise in Quality management process and audit
- Established research partnership for oncology products and services with academic and hospital-based programs
Razelle Kurzrock, MD
Chief medical advisor & Co-founder, CUREMATCH Director, Rare tumor clinic, UCSD
- A board-certified medical oncologist and a renowned expert in precision medicine
- With over 400 peer-reviewed publications, she has a strong record of competitive grant funding
- Developed one of the largest Phase I clinical trial programs at MD Anderson Cancer Center, Texas
- Executive Committee of Board of Directors, National Comprehensive Cancer Network® (NCCN®)
Himabindu Gaddipati, MD, EMTM
Chairman and MD, VCR Park CEO, Lumiseek
- Clinical hemato-oncologist and geneticist
- Over 2 decades of expertise in Basic science, Clinical trials, Precision medicine, Technology
commercialization (Wharton), Regulation (FDA) and IP (NCI) - Founder at Biolara Inc.
- Executive Director, Queens NRI Hospital, Visakhapatnam
Payal Keswarpu, MD, DNB
Pathology Lab Director, VCR Park
- Pathologist with 20 years of experience in molecular pathology services and development of
esoteric assays - Experience in working with laboratories in precision oncology space in US & India
- Expertise in Quality management process and audit
- Established research partnership for oncology products and services with academic and hospital-based programs